newsfilter
← Latest News
GlobeNewswire·

Albireo Announces Positive Topline Data from Phase 1 Study of A3907

– First oral, systemic ASBT inhibitor was safe and well tolerated – Secondary and exploratory objectives show favorable pharmacokinetics and systemic exposure, while providing target engagement signals – Company on track to initiate planned a